SCHEMBL4825515

SCHEMBL4825515

CCOC(=O)C(Cc1cnc(Nc2ccccc2)nc1Nc1ccccc1)c1cc(OC)ccc1OC

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.48
MAPK9 P45984 1/20 0.48
PTK2 Q05397 1/20 0.47
MAPT P10636 2/20 0.45
EGFR P00533 5/20 0.44
JAK3 P52333 2/20 0.44
ITK Q08881 1/20 0.43
JAK2 O60674 1/20 0.43
HDAC1 Q13547 1/20 0.43
ULK1 O75385 1/20 0.42
CDK4 P11802 1/20 0.42
CDK2 P24941 1/20 0.42
BTK Q06187 4/20 0.42
SYK P43405 1/20 0.42
CHEK1 O14757 1/20 0.41
NTRK2 Q16620 1/20 0.41
SHMT2 P34897 1/20 0.41
SIRT5 Q9NXA8 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4770594 0.91 MAPK9 (0.51) MAPK8MAPK9PTK2EGFRJAK3
SCHEMBL4767481 0.91 PTK2 (0.49) MAPK8MAPK9PTK2MAPTEGFR
SCHEMBL4767520 0.86 MAPK8 (0.54) MAPK8MAPK9PTK2MAPTEGFR
SCHEMBL4771570 0.84 MAPK8 (0.50) MAPK8MAPK9PTK2EGFRJAK3
SCHEMBL4773873 0.81 MAPK8 (0.51) MAPK8MAPK9PTK2EGFRJAK3
SCHEMBL4771563 0.80 EGFR (0.49) MAPK8MAPK9MAPTEGFRJAK3
SCHEMBL4764815 0.80 CHEK1 (0.49) MAPK8MAPK9PTK2EGFRJAK3
SCHEMBL4770474 0.79 EGFR (0.47) PTK2MAPTEGFRJAK3ITK
SCHEMBL4765299 0.79 SYK (0.49) MAPK8MAPK9EGFRJAK3ITK
SCHEMBL4774864 0.78 CHEK1 (0.50) MAPK8MAPK9PTK2EGFRJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098332-B2 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones HOFFMANN-LA ROCHE INC. (US) 2006-08-29 US claimed
EP-1581531-A1 PYRIDINO[2,3-D]PYRIMIDINE DERIVATIVES AS SELECTIIVE KDR AND FGFR INHIBITORS F. Hoffmann-La Roche AG (CH) 2005-10-05 EP claimed
WO-2004056822-A1 PYRIDINO `2, 3-D! PYRIMIDINE DERIVATIVES AS SELECTIVE KDR AND FGFR INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-08 WO claimed
US-20040122029-A1 Novel dihydropyridinone compounds LIU JIN-JUN (US) 2004-06-24 US claimed
EP-1581531-B1 PYRIDINO¬2,3-D PYRIMIDINE DERIVATIVES AS SELECTIIVE KDR AND FGFR INHIBITORS HOFFMANN LA ROCHE (CH) 2008-02-27 EP disclosed
US-7098332-B2 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones HOFFMANN-LA ROCHE INC. (US) 2006-08-29 US disclosed
EP-1581531-A1 PYRIDINO[2,3-D]PYRIMIDINE DERIVATIVES AS SELECTIIVE KDR AND FGFR INHIBITORS F. Hoffmann-La Roche AG (CH) 2005-10-05 EP disclosed
WO-2004056822-A1 PYRIDINO `2, 3-D! PYRIMIDINE DERIVATIVES AS SELECTIVE KDR AND FGFR INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-08 WO disclosed
US-20040122029-A1 Novel dihydropyridinone compounds LIU JIN-JUN (US) 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122029-A1 Novel dihydropyridinone compounds FGFR1, FGFR3, FGFR4 MAPK8 477/4885MAPK9 536/4885PTK2 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.